Search - tctmd.com

Displaying 141 - 160 of 186

Sort: Relevancy | Date

Presentation TCT 2016

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Presenter: Roxana Mehran, Pascal Vranckx, Robert A. Harrington

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

News Daily News

Amid Sparse Data on Infection After ASD Closure, Experts Urge Focus on Dental Health

Yael L. Maxwell

September 26, 2016

News Daily News

Tweet This: Digital Health a Research Priority for Emergency Cardiac Care, AHA Says

Yael L. Maxwell

June 22, 2016

News Opinion Editor's Corner

数据的礼物：医学期刊支持将数据公开披露作为发表的前提

Shelley Wood

January 24, 2016

News Opinion Editor's Corner

The Gift of Data: Medical Journals Back Public Data Disclosure as Prerequisite for Publishing

Shelley Wood

January 24, 2016

News Opinion Editor's Corner

El Regalo de los Datos: Las Revistas Médicas Exigen que se Hagan Públicos los Datos como un Requisito Indispensable en Materia de Publicación

Shelley Wood

January 24, 2016

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Presenter: Lisa K. Jennings, Matthew T. Roe, Pascal Vranckx

October 14, 2015

Presentation TCT 2015

Is Dropping Aspirin the Magic Solution?

Presenter: John A. Bittl, Gary L. Schaer, Pascal Vranckx

October 12, 2015

Presentation TCT 2015

The 10 Most Common Statistical Mistakes and Misinterpretations I See Again and Again

Presenter: Robert A. Harrington, Pascal Vranckx, Sanjay Kaul

October 11, 2015

Presentation TCT 2015

When Is the Primary Endpoint Not Enough? Pitfalls in Primary Endpoint Selection and Assumptions, Power, and More

Presenter: Robert A. Harrington, Pascal Vranckx

October 11, 2015

Presentation TCT 2015

How to Assess the Quality of Evidence From Peer-Reviewed Manuscripts: The Statistical Reviewers Vantage Point

Presenter: Robert A. Harrington, Pascal Vranckx, Jan Tijssen

October 11, 2015

Presentation TCT 2015

What Are the Management Options for the Patient With AF and DES?

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Pascal Vranckx

October 11, 2015

News Features

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

Presentation TCT 2014

Thoughtful Insights

Presenter: Pascal Vranckx

September 17, 2014

Advertisement

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Amid Sparse Data on Infection After ASD Closure, Experts Urge Focus on Dental Health

Tweet This: Digital Health a Research Priority for Emergency Cardiac Care, AHA Says

数据的礼物：医学期刊支持将数据公开披露作为发表的前提

The Gift of Data: Medical Journals Back Public Data Disclosure as Prerequisite for Publishing

El Regalo de los Datos: Las Revistas Médicas Exigen que se Hagan Públicos los Datos como un Requisito Indispensable en Materia de Publicación

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Is Dropping Aspirin the Magic Solution?

The 10 Most Common Statistical Mistakes and Misinterpretations I See Again and Again

When Is the Primary Endpoint Not Enough? Pitfalls in Primary Endpoint Selection and Assumptions, Power, and More

How to Assess the Quality of Evidence From Peer-Reviewed Manuscripts: The Statistical Reviewers Vantage Point

What Are the Management Options for the Patient With AF and DES?

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Thoughtful Insights

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content